Hypotonic intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in mice
1996

Hypotonic Cisplatin Chemotherapy for Cancer in Mice

Sample size: 60 publication Evidence: moderate

Author Information

Author(s): A Kondo, M Maeta, A Oka, S Tsujitani, M Ikeguchi, N Kaibara

Primary Institution: First Department of Surgery, Faculty of Medicine, Tottori University

Hypothesis

The study investigates the effect of fluid osmolarity on the therapeutic efficacy of intraperitoneal cisplatin chemotherapy.

Conclusion

Cisplatin administered in hypotonic solution significantly improves therapeutic efficacy and prolongs survival in mice with peritoneal carcinomatosis.

Supporting Evidence

  • Uptake of cisplatin in hypotonic solution was significantly greater than in isotonic or hypertonic solutions.
  • The LD50 value of cisplatin in hypotonic solution was lower than in isotonic and hypertonic solutions.
  • Survival of mice given cisplatin in hypotonic solution was significantly prolonged compared to those given isotonic or hypertonic solutions.

Takeaway

Using a special type of fluid, cisplatin can work better to help mice with cancer live longer.

Methodology

The study involved administering cisplatin in hypotonic, isotonic, and hypertonic solutions to mice with tumors and measuring drug uptake and survival rates.

Limitations

The results may not apply to peritoneal carcinomatosis with multiple solid tumors.

Participant Demographics

Male ddy mice and male Donryu rats were used in the experiments.

Statistical Information

P-Value

p<0.01

Confidence Interval

11.2-13.1

Statistical Significance

p<0.01

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication